Amy L. Cummings - Concepedia

Author

Amy L. Cummings

University of California, Los Angeles ORCID

Also Known As

A. Cummings, Aaron Andre, Amy Cummings, Amy L Cummings, Amy L. Cummings, Amy Lauren Cummings, Cummings, Amy L

201

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles University of California San Diego Tennessee Oncology Columbia University Institut Gustave Roussy

About

Amy L. Cummings is an author at University of California, Los Angeles specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	658
2	Immunology	2	2	64
3	Pathology	2	2	34
4	Health Sciences	1	1	17
5	Health Policy	1	1	28

Amy L. Cummings

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman, Journal of Thoracic Oncology Advanced NsclcOncologyMedicineReceptor Tyrosine KinasePhase Ii Study	2018	577
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, Cancer Discovery	2023	166
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Nature	2024	117
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer Siwen Hu‐Lieskovan, Aaron Lisberg, Jesse M. Zaretsky, Clinical Cancer Research	2019	68
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44 Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu, Nature Cancer Cancer ImmunosurveillanceNon-small-cell Lung CancerMedicineMutational Landscape InfluencesImmunology	2020	47
Consent document translation expense hinders inclusive clinical trial enrolment Maria A. Velez, Beth A. Glenn, Maria García-Jímenez, Nature Informed ConsentClinical TrialsResearch EthicsHealth Policy	2023	28
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation Charlene M. Fares, Timothy J. Williamson, Matthew K. Theisen, JCO Clinical Cancer Informatics	2018	25
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer Edward B. Garon, Alexander I. Spira, Melissa L. Johnson, Clinical Cancer Research	2021	22
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach, Lung Cancer Autoimmune DiseaseThyroid DysfunctionFrequent Event Post-treatmentMedicineThyroid Disease	2021	17
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC). Jonathan W. Goldman, Amy L. Cummings, Melody Mendenhall, Journal of Clinical Oncology PathologyPharmacotherapyMetronomic ChemotherapyImmunotherapyIntermittent Low-dose Temozolomide	2022	17

Page 1